What will you achieve with mRNA? Life-changing medicines, vaccines and more made possible by the latest improvements in mRNA and LNP technology.
This page is under construction – please come back soon
Our applications
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Dummy application
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris elementum nulla vel massa posuere interdum. Sed a neque augue. Ut et felis ut eros...
Download
Read more about Title
Title
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat
Read more
Read more about Dolor sit amet lorem
Dolor sit amet lorem
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat
Read more
Read more about Title
Title
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat
Read more
Read more about Title
Title
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat
Read moreExamples of what
can be done with mRNA
Novel therapies for rare metabolic disorders
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Corona vaccines
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Next-generation vaccines
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Immuno-oncology
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Last one
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Discovering the function of genes and rescuing knock- downs/knock-outs
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
(trans)Differentiation of (stem)-cells and treatment of organoids
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Targeted therapy for CKD
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
Bone-regeneration
At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.
These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.
To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization. test
Customers
What our customers say
“RiboPro offers not only high-quality mRNA but also very helpful and fast support on all matters concerning mRNA.”
Jana Schembera
Researcher
“We are RiboPro customer since 2020 and we are satisfied about their products. We also appreciate very much the customer service. The team is very cooperative and helpful, communication is clear, precise and always on time.”
Chiara Gai
“RiboPro provided both the expert support and synthesized the high-quality mRNA to make our first gene manipulation experiments a resounding success. Furthermore, RiboPro was able to provide the mRNA constructs at an inordinate speed.”
Aviad Pato
Head of research at Gamida Cell
“I ordered a custom Cap-1 mRNA from RiboPro for in vivo research. The custom mRNA from RiboPro expressed as the target protein in the mammalian cell line and maintained good level of protein expression in vivo (mouse). They delivered me the mRNA product in a timely manner and gave useful comments, responses and transparency to my questions for my order. So, I would recommend users trying the RiboPro.”
Lee Jenny
“The high quality, stable and non-immunogenic mRNA generated by Ribopro is extremely suitable to meet our needs. The company also offers the qualified expert advice allowing the optimization of our experimental protocols.”
Prof. Dr. Elena Levtchenko
Professor at KU Leuven